/ATHE
ATHE Stock - Alterity Therapeutics Limited
Healthcare|BiotechnologyNASDAQ
$3.09+1.98%
+$0.06 (+1.98%) • Dec 19
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.7
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.40
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ATHE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.06 – $3.12
TARGET (TP)$3.55
STOP LOSS$2.84
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.05
52W High$7.00
52W Low$2.20
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.44M | $4.02M | $3.92M | $5.12M | $4.34M |
| Gross Profit | $5.31M | $3.80M | $3.63M | $4.76M | $3.98M |
| Gross Margin | 97.7% | 94.7% | 92.7% | 92.9% | 91.7% |
| Operating Income | $-14,574,286 | $-19,601,709 | $-14,636,142 | $-15,501,987 | $-15,178,544 |
| Net Income | $-12,147,828 | $-19,123,464 | $-13,806,515 | $-12,847,061 | $-15,309,353 |
| Net Margin | -223.4% | -475.8% | -352.5% | -250.7% | -352.8% |
| EPS | $-1.14 | $-3.12 | $-3.42 | $-3.18 | $-5.40 |
Company Overview
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
50%
Hold / Neutral
1
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
1 Bullish1 Neutral/Bearish
Price Targets
$8
Average Target
↑ 158.9% Upside
Now
$8
Low
$8
Average
$8
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 3rd 2025 | The Benchmark Company | Downgrade | Hold | - |
| December 12th 2024 | Maxim Group | Initiation | Buy | $8 |
Earnings History & Surprises
ATHEBeat Rate
100%
Last 7 quarters
Avg Surprise
+66.6%
EPS vs Estimate
Beats / Misses
7/0
Last 12 quarters
Latest EPS
$-0.40
Q3 2025
EPS Surprise History
Q2 23
No data
Q1 24
No data
Q1 24
+97.5%
$-0.00vs$-0.11
Q2 24
No data
Q3 24
+96.2%
$-0.00vs$-0.05
Q1 25
No data
Q1 25
+99.9%
$-0.00vs$-0.53
Q3 25
+7.2%
$-0.40vs$-0.43
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 28, 2025 | $-0.43 | $-0.40 | +7.2% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | — | — | — | — |
Q1 2025 | Feb 28, 2025 | $-0.53 | $-0.00 | +99.9% | ✓ BEAT |
Q1 2025 | Feb 3, 2025 | — | $-0.00 | — | — |
Q3 2024 | Aug 29, 2024 | $-0.05 | $-0.00 | +96.2% | ✓ BEAT |
Q2 2024 | Apr 11, 2024 | — | $-0.00 | — | — |
Q1 2024 | Feb 28, 2024 | $-0.11 | $-0.00 | +97.5% | ✓ BEAT |
Q1 2024 | Jan 30, 2024 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q1 2023 | Mar 31, 2023 | $-0.12 | $-0.00 | +99.0% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-1.81 | $-1.11 | +38.6% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q3 2022 | Aug 30, 2022 | $-1.97 | $-1.43 | +27.5% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | — | $-0.00 | — | — |
Q1 2022 | Feb 28, 2022 | — | $-0.98 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.00 | — | — |
Q3 2021 | Aug 31, 2021 | $-1.43 | — | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Q1 2021 | Feb 25, 2021 | — | — | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.01 | — | — |
Latest News
Alterity Therapeutics Presents Data On Orthostatic Hypotension From Its ATH434-201 Phase 2 Clinical Study In Multiple System Atrophy
➖ NeutralBenzinga•Nov 10, 2025, 12:27 PM
Alterity Therapeutics Reports Stronger ATH434 Phase 2 Efficacy Signal, Positive Advanced MSA Data, Sees USD $2.4 Billion Peak Sales Potential
📈 PositiveBenzinga•Oct 31, 2025, 11:29 AM
Alterity Therapeutics Presents Data From ATH434-201 Randomized, Double-Blind Phase 2 Clinical Trial In MSA At 2025 International Congress Of Parkinson's Disease And MDS
➖ NeutralBenzinga•Oct 9, 2025, 11:27 AM
Alterity to Present Multiple System Atrophy Drug Trial Results at Major Parkinson's Conference in Hawaii
📈 PositiveBenzinga•Oct 2, 2025, 11:37 AM
Alterity Therapeutics Phase 2 Trial Shows ATH434 Slowed Progression Of Rare Brain Disorder MSA
📈 PositiveBenzinga•Sep 15, 2025, 11:26 AM
Alterity Therapeutics Raises $20M to Advance FDA Path for Promising Neurodegenerative Drug
📈 PositiveBenzinga•Sep 8, 2025, 11:36 AM
Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Sep 8, 2025, 11:00 AM
Trading Halt: Halted at 7:26:36 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Sep 3, 2025, 11:26 PM
Frequently Asked Questions about ATHE
What is ATHE's current stock price?
Alterity Therapeutics Limited (ATHE) is currently trading at $3.09 per share. The stock has moved +1.98% today.
What is the analyst price target for ATHE?
No analyst price targets are currently available for this stock.
What sector is Alterity Therapeutics Limited in?
Alterity Therapeutics Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ATHE's market cap?
Alterity Therapeutics Limited has a market capitalization of $0.03 billion, making it a small-cap company.
Does ATHE pay dividends?
No, Alterity Therapeutics Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANVS
Annovis Bio, Inc.
$3.65
Mkt Cap: $0.1B
BTAI
BioXcel Therapeutics, Inc.
$1.73
Mkt Cap: $0.0B
DYAI
Dyadic International, Inc.
$1.00
Mkt Cap: $0.0B
EVAX
Evaxion Biotech A/S
$4.70
Mkt Cap: $0.0B
GBIO
Generation Bio Co.
$5.54
Mkt Cap: $0.0B
IGC
IGC Pharma, Inc.
$0.30
Mkt Cap: $0.0B
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$0.79
Mkt Cap: $0.0B
MAIA
MAIA Biotechnology, Inc.
$1.22
Mkt Cap: $0.0B
MURA
Mural Oncology plc
$2.04
Mkt Cap: $0.0B
NNVC
NanoViricides, Inc.
$1.24
Mkt Cap: $0.0B
Explore stocks similar to ATHE for comparison